focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Diurnal shares more than double on takeover bid

Tue, 30th Aug 2022 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Diurnal Group PLC, shares surge to 26.19 pence from Friday's close of 11.25p, 12-month range 9.5-67.9p. The pharmaceutical company focused on hormonal diseases agrees to be taken over by Neurocrine Biosciences Inc in deal worth GBP48.3 million. Neurocrine is offering 27.5p, cash, for each Diurnal share. Diurnal directors unanimously recommend deal. "We believe that the acquisition is compelling for Diurnal's shareholders given the risks associated with achieving Diurnal's vision of creating a profitable business, in particular the ongoing commercial roll out of Diurnal's products in Europe and the execution of key clinical studies, in addition to the substantial shareholder dilution that is likely to result from accessing the capital required to deliver this vision," says Non-Executive Chair Anders Harfstrand.

----------

SIMEC Atlantis Energy Ltd, up 31% at 2.03p, 12-month range 0.97p-5.3p. The sustainable energy generation firm secures necessary grid variations for the 230 megawatt/460 megawatt hour battery energy storage system at the Uskmouth site and has completed the novation of the grid connection agreement. "With excellent progress being made, the project is on track to be operational by 2024," it says. Adds it now has no loans outstanding with any SIMEC group company.

----------

MyCelx Technologies Corp, up 14% at 48.36p, 12-month range 30.55p-92.00p. The clean water and air technology firm secures new purchase order from SABIC Agri-Nutrients, a SABIC affiliate, to provide clean water for optimal performance in their fertiliser production process. Also wins short-term emergency response project with a independent petrochemical company in Saudi Arabia and secures renewal of two water treatment contracts with long-standing customers in the Middle East. "These projects underpin the 2022 revenue forecast, and the company remains on track to meet current guidance," it says.

----------

AIM - LOSERS

----------

Petroneft Resources PLC, down 28% at 0.645p, 12-month range 0.65p-4.88p. Reports temporary suspension of oil acceptance and transfer from Licence 61 by Nord Imperial LLC. In 2009, contract was signed with Nord Imperial to cover storage and transfer of oil by pipeline from Licence 61 to the Transneft Entry point at Zavyalovo. Petroneft says it has considered contract tariff to be "significantly higher than normal market rates" for some time. Says payments were made to Nord Imperial at reduced levels amid no progress in finding "more equitable" outcome and, in response, Nord Imperial has temporarily suspending the acceptance of oil and transfer. "As the company currently have no other export route from Licence 61, Petroneft is progressively shutting down its wells until the situation can be resolved," it says.

----------

Joules Group PLC, down 7.5% at 23.58p, 12-month range 19.41p-257.00p. Retailer insists it continues in "positive" discussions with Next over a possible investment, despite Sky News over the weekend reporting that talks had stalled. Sky News said it has learnt the two companies are not close to agreeing the terms of an investment from Next, and the FTSE 100-listed retailer had not received enough financial information to allow it to make a formal offer to the Joules board. There were also doubts that Next would want to proceed with a deal at 33p per share or more given Joules shares closed at 25.5p on Friday. The stock has fallen 82% since the start of 2022, and shares had closed at 33p the day before the companies confirmed they were in talks over the potential equity investment.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.